GlassScriptPhysician profile
Lukas D Veith
NPI 1316330426
$4,825.89
in general payments reported to CMS, 2019-2025
37 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,790 · 2022: $1,576 · 2023: $1,183 · 2024: $57.11 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $802.09 | 2021-2023 | |
| Novo Nordisk INC | $707.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $497.96 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $310.98 | 2021-2023 | |
| Lilly USA, LLC | $299.96 | 2021-2023 | Trulicity, Humalog, Basaglar |
| Glaxosmithkline, LLC. | $189.66 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $184.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.46 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $174.82 | 2021-2025 | Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $167.43 | 2021 | |
| Dexcom, INC. | $126.58 | 2021-2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.49 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $91.50 | 2022 | |
| Abbott Laboratories | $88.98 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $87.98 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lukas Veith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.